Document detail
ID
oai:HAL:hal-02988544v1
Topic
[SDV.IMM.VAC]Life Sciences [q-bio]...Author
van den Eeckhout, Bram van Hoecke, Lien Burg, Elianne van Lint, Sandra Peelman, Frank Kley, Niko Uzé, Gilles Saelens, Xavier Tavernier, Jan Gerlo, SarahLangue
enEditor
HAL CCSD;Nature Research
Category
sciences: life sciences
Year
2020
listing date
12/7/2023
Keywords
cells influenza il-1βAbstract
International audience; Annual administration and reformulation of influenza vaccines is required for protection against seasonal infections.
However, the induction of strong and long-lasting T cells is critical to reach broad and potentially lifelong antiviral immunity.
The NLRP3 inflammasome and its product interleukin-1β (IL-1β) are pivotal mediators of cellular immune responses to influenza, yet, overactivation of these systems leads to side effects, which hamper clinical applications.
Here, we present a bypass around these toxicities by targeting the activity of IL-1β to CD8 + T cells.
Using this approach, we demonstrate safe inclusion of IL-1β as an adjuvant in vaccination strategies, leading to full protection of mice against a high influenza virus challenge dose by raising potent T cell responses.
In conclusion, this paper proposes a class of IL-1β-based vaccine adjuvants and also provides further insight in the mechanics of cellular immune responses driven by IL-1β.
npj Vaccines (2020) 5:64 ; https://doi.
van den Eeckhout, Bram,van Hoecke, Lien,Burg, Elianne,van Lint, Sandra,Peelman, Frank,Kley, Niko,Uzé, Gilles,Saelens, Xavier,Tavernier, Jan,Gerlo, Sarah, 2020, Specific targeting of IL-1β activity to CD8+ T cells allows for safe use as a vaccine adjuvant, HAL CCSD;Nature Research
